221
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
MARKETING ANALYSIS OF DRUGS USED IN OBSTETRICS AND GYNECOLOGY
Kozokboeva G.A.
Rajabova N.Kh.
Tashkent Pharmaceutical Institute, Tashkent, Republic of Uzbekistan
https://doi.org/10.5281/zenodo.17333251
Relevance:
at present, the prevalence of obstetric and gynecological diseases is increasing
worldwide, which makes this issue one of the most urgent problems in the global healthcare system.
According to the World Health Organization, diseases affecting women’s reproductive health have
not only medical but also socio-economic consequences. The rise in these conditions is associated
with several factors, including ecological, socio-economic, nutritional and lifestyle-related,
infectious, demographic, as well as genetic and endocrine factors. Statistical data indicate that
polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, and vaginitis are among
the most common disorders globally. In obstetric and gynecological practice, medicinal products are
primarily used to facilitate labor, ensure contraception, preserve or terminate pregnancy, treat
hormonal imbalances, and prevent or manage infections. Based on these aspects, conducting a
marketing analysis of drugs used in this field within the local pharmaceutical market is highly
relevant.
Purpose of the study:
to conduct a marketing analysis of the pharmaceutical market of the
Republic of Uzbekistan regarding medicinal products used in obstetric and gynecological practice.
Materials and methods:
the study was carried out using data from the State Register of
Medicinal Products, Medical Devices, and Medical Equipment permitted for use in medical practice
in the Republic of Uzbekistan for the years 2020–2024. The drug assortment was analyzed employing
content analysis as well as assortment breadth, completeness, depth, and renewal index as
methodological approaches.
Results:
the analysis of drugs used in obstetrics and gynecology by pharmacotherapeutic
groups revealed the following: in 2020, a total of 55 drugs were registered (foreign – 48, CIS – 5,
local – 2), whereas in 2021 the figure increased to 77 (foreign – 62, CIS – 4, local – 11). In 2022, 83
drugs were recorded (foreign – 65, CIS – 4, local – 14), in 2023 – 78 (foreign – 62, CIS – 2, local –
14), and in 2024 – 69 (foreign – 53, CIS – 2, local – 14). Thus, the drug assortment expanded in 2021–
2022, but a gradual decline was observed in 2023–2024. Foreign drugs accounted for the majority
each year (87% in 2020 and 77% in 2024). Nevertheless, the share of locally produced drugs increased
steadily: from 3.6% in 2020 to 20.3% in 2024. Among the pharmacotherapeutic groups, G01A
(antimicrobial agents and antiseptics) represented the largest segment. The number of foreign
products in this group rose from 22 in 2020 to 43 in 2022 and remained stable thereafter, while local
production appeared in 2022 (10–12 items). G02 (other gynecological preparations) demonstrated a
gradual decrease (15 in 2020 vs. 4 in 2024). G02A (uterotonic drugs), represented by one item in
2020, expanded with the introduction of local alternatives in 2022–2024, indicating the development
of domestic production. G03X (sex hormones and modulators of the genital system) remained stable
with 1–2 foreign drugs annually. L02A (hormone antagonists and related agents) and H01B (pituitary
posterior lobe hormones) did not change, consistently showing 1–2 foreign drugs per year. J01X and
J02A (systemic antibacterials and antifungals) were rarely used, appearing only in certain years.
Furthermore, non-classified drugs were identified: 3 in 2020, 6 in 2022, and 4 in 2024, reflecting
existing challenges in classification and standardization.
222
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
Conclusions:
the increase in obstetric and gynecological diseases is associated with complex
factors and requires comprehensive research, early diagnosis, and the development of effective
treatment approaches. During 2020–2024, the market of drugs used in obstetrics and gynecology was
dominated by foreign products, although local production has been gradually strengthening. The most
significant progress has been observed in the production of antimicrobial and uterotonic drugs. At the
same time, reducing the number of non-classified drugs and aligning them with the ATC system
remains an important scientific and practical task for the future.
